|
T31411 |
DHA-37
|
DHA 37 |
Others
|
|
DHA-37 is an inducer of autophagic cell death through upregulation of HMGB1 in A549 cells. |
|
T38127 |
PNPS-DHA
|
|
Others
|
|
pNPS-DHA is an arylamide derivative of docosahexaenoyl ethanolamide that has anti-allergic activity.1It inhibits degranulation of RBL-2H3 mast cells (IC50= 15 μM).pNPS-DHA (1,000 mg/kg) inhibits IgE-dependent passive cut... |
|
T70006 |
DHA-paclitaxel
|
|
Others
|
|
DHA-paclitaxel, also know as Taxoprexin, is prodrug comprised of the naturally occurring omega-3 fatty acid docosahexaenoic acid (DHA) covalently conjugated to the anti-microtubule agent paclitaxel. Because tumor cells t... |
|
T11079 |
NMI 8739
|
n-docosahexaenoyl dopamine,Dha-DA conjugate |
Dopamine Receptor
|
|
|
|
T19294 |
Docosahexaenoic Acid methyl ester
|
Methyl docosahexaenoate,all cis-DHA methyl ester |
Others
|
|
Docosahexaenoic Acid methyl ester (all cis-DHA methyl ester) is a methylated docosahexaenoic acid analog that can be inserted into membrane phospholipids without being oxidized or hydrolyzed. |
|
T64367 |
Fmoc-Dha-OH
|
2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)prop-2-enoic acid |
Others
|
|
Fmoc-Dha-OH (2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)prop-2-enoic acid) is a biologically active compound that is an important component of peptide and protein synthesis. It is commonly used in the synthesis of pept... |
|
T85270 |
Docosahexaenoic Acid Alkyne
|
Click Tag™ DHA Alkyne,FA 22:8 |
Others
|
|
Docosahexaenoic acid alkyne, an ω-alkyne derivative of docosahexaenoic acid, enables Cu(I)-catalyzed cycloaddition with azide-containing molecules for efficient click chemistry applications. It can be further utilized to... |
|
T85200 |
17(R)-Resolvin D4
|
4(S),5(R),17(R)-trihydroxy-DHA,17(R)-RvD4 |
Others
|
|
17(R)-Resolvin D4 (17(R)-RvD4) is an epimer of RvD4, generated through the aspirin-induced modification process. |
|
T70005 |
LY3325656
|
|
Others
|
|
LY3325656 is a GPR142 agonist suitable for clinical testing in human. LY3325656 demonstrated anti-diabetic benefits in pre-clinical studies and
ADME/PK properties suitable for human dosing. LY3325656 is the first GPR1... |
|
T3175 |
LDHA-IN-4
|
AZ 33,AZ-33,LDHA Inhibitor,AZ33 |
Dehydrogenase
|
|
LDHA-IN-4 (AZ33) is an LDHA inhibitor. Binding affinity to 6-His-tagged human LDHA (2 to 322 amino acid residue) expressed in Escherichia coli BL21 (DE3) cells by SPR analysis with an active value of 0.093 μM. |
|
T39805 |
LDHA-IN-3
|
PSTMB,1-(phenylseleno)-4-(trifluoromethyl) benzene |
Dehydrogenase
|
|
LDHA-IN-3 (1-(phenylseleno)-4-(trifluoromethyl) benzene) is a potent non-competitive lactate dehydrogenase (LDHA) inhibitor with an IC50 value of 145.2 nM.LDHA-IN-3 is a selenobenzene compound that can be used in cancer ... |
|
T74235 |
DHAPC
|
1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine |
Liposome
|
|
DHAPC (1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine) can be used as a fluorine-18 radiolabeling agent for PET imaging of prostate cancer. |
|
T35508 |
(±)13-HDHA
|
|
Others
|
|
(±)13-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. Fresh water hydra was shown to metabolize DHA to 1... |
|
T36607 |
(±)8-HDHA
|
|
Others
|
|
(±)8-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. (±)8-HDHA is a potential marker of oxidative stress... |
|
T35505 |
(±)11-HDHA
|
|
Others
|
|
(±)11-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. DHA is metabolized to 11(S)-HDHA by human platelet... |
|
T35512 |
(±)16-HDHA
|
|
Others
|
|
(±)16-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. (±)16-HDHA is a potential marker of oxidative stre... |
|
T35509 |
(±)14-HDHA
|
|
Others
|
|
(±)14-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. DHA is metabolized to 14(S)-HDHA by human platelet... |
|
T36606 |
(±)7-HDHA
|
|
Others
|
|
(±)7-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. Enzymatic transformation of DHA by RBL-1 cells and ... |
|
T36602 |
(±)4-HDHA
|
|
Others
|
|
(±)4-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. Enzymatic transformation of DHA by RBL-1 cells also... |
|
T36042 |
17(R)-HDHA
|
|
Others
|
|
Resolvins are a group of polyhydroxylated metabolites of docosahexaenoic acid (DHA) found in the inflammatory exudates of aspirin-treated experimental animals. 17(R)-HDHA is the primary oxygenation product of DHA when ex... |
|
T35504 |
(±)10-HDHA
|
|
Others
|
|
(±)10-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro.[1][2] It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes.[3][4][5] (±)10-HDHA is a potential marker of... |
|
T36601 |
(±)17-HDHA
|
|
Others
|
|
(±)17-HDHA is an autoxidation product of docosahexaenoic acid in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. 17(S)-HDHA could be produced by enzymatic oxidation of D... |
|
T35997 |
22-HDHA
|
|
Others
|
|
22-HDHA is an oxidation product of docosahexaenoic acid . In vitro, it is formed upon incubation of rat liver microsomes with DHA and NADPH and also by the human cytochrome P450 (CYP) isoform CYP4F3B in BTI-TN-5B1-4 micr... |
|
T37488 |
10(S),17(S)-DiHDHA
|
|
Others
|
|
Protectin D1 (also known as neuroprotectin D1 when produced in neuronal tissues) is a DHA-derived dihydroxy fatty acid that exhibits potent protective and anti-inflammatory activities. 10(S),17(S)-DiHDHA is a DHA metabol... |
|
T84487 |
17(S)-HpDHA
|
17(S)-hydroperoxy Docosahexaenoic Acid |
Others
|
|
17(S)-HpDHA, primarily produced by the 15-Lipoxygenase (LOX) isoenzymes h15-LOX-1 and h15-LOX-2 from docosahexaenoic acid (DHA), is a key regulator in epoxide synthesis through allosteric modulation. Additionally, it eff... |
|
T37259 |
14(S)-HDHA
|
|
Others
|
|
Docosahexaenoic acid is a nutritionally-derived ω-3 fatty acid that is abundant in the brain and the retina and is thought to be important in early development and for therapeutic approaches to inflammatory disorders and... |
|
T24939 |
Virodhamine trifluoroacetate
|
Virodhamine-trifluoroacetate,Virodhamine trifluoroacetate salt |
Others
|
|
Virodhamine trifluoroacetate is an antagonist of endogenous cannabinoid receptor mixed that acts by being a full agonist at GPR55 and CB2 and partial antagonist at CB1. |
|
T60995 |
LDHA/PDKs-IN-2
|
|
Others
|
|
LDHA/PDKs-IN-2 (compound 20k) is a potent LDHA and PDKs dual inhibitor with IC50 values of 0.7 and 1.6 μM, respectively. LDHA/PDKs-IN-2 increases oxygen consumption as well as decreases the lactate formation. LDHA/PDKs-I... |
|
T30217 |
Avadharidine
|
|
Others
|
|
Avadharidine is a biochemical. |
|
T73222 |
LDHA-IN-5
|
|
Others
|
|
LDHA-IN-5 is a novel and potent inhibitor targeting both glycolate oxidase (GO) and lactate dehydrogenase A (LDHA), designed for the treatment of primary hyperoxaluria. |
|
T61339 |
LDHA/PDKs-IN-1
|
|
Others
|
|
LDHA/PDKs-IN-1 (compound 20e) is a highly effective dual inhibitor of PDKs and LDHA, displaying IC50 values of 0.8 μM and 0.15 μM, respectively. It significantly suppresses A549 cell proliferation (EC50 = 13.2 μM), reduc... |
|
T64371 |
Virodhamine
|
O-arachidonoyl ethanolamine |
Cannabinoid Receptor
|
|
Virodhamine (O-arachidonoyl ethanolamine), an endocannabinoid, is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine can be used for the research of neurological disorders such as Alzheimer's disea... |
|
T35947 |
17(S)-HDHA
|
|
Others
|
|
17(S)-HDHA is a primary mono-oxygenation product of docosahexaenoic acid in human whole blood, human leukocytes, and mouse brain. 17(S)-HDHA serves as a precursor to 17(S)-resolvins and has intrinsic biological activity,... |
|
T19319 |
Ethyl docosa-4,7,10,13,16,19-hexaenoate
|
|
Others
|
|
Ethyl cis-4,7,10,13,16,19-Docosahexaenoate, the ethyl ester of Docosahexaenoate (DHA), is selectively enriched in the ethyl ester fraction through the alcoholysis process involving fatty acid ethyl esters from tuna oil a... |
|
T74757 |
Didocosahexaenoin
|
|
Others
|
|
Didocosahexaenoin, an omega-3 derivative and diglyceride of DHA synthesized from DHA triglycerides, significantly decreases mitochondrial membrane potential and stimulates ROS (reactive oxygen species) production. It ind... |
|
T12707 |
Resolvin D2
|
RvD2 |
Others
|
|
Resolvin D2 is a docosahexaenoic acid (DHA) metabolite, with anti-inflammatory and anti-infective activities. |
|
T41059 |
Resolvin D3
|
RvD3 |
Others
|
|
Resolvin D3 (RvD3) is a dysregulated mediator originating from docosahexaenoic acid (DHA). It plays a crucial role in reducing arthritic inflammation. |
|
T31218 |
DBHDA
|
|
Others
|
|
DBHDA is a reagent to convert a Cys into a Dha moiety by reacting with a C-terminal Cys residue and thus allowing the use of recombinant Ubl G76C mutants to prepare probes. |
|
T37238 |
(±)19(20)-EpDPA
|
|
Others
|
|
EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-de... |
|
T36868 |
4-oxo Docosahexaenoic Acid
|
|
Others
|
|
4-oxo Docosahexaenoic acid (4-oxo DHA) is a putative metabolite of DHA with antiproliferative and PPARγ agonist activity. It inhibits the growth of several triple negative breast cancer cell lines (MCF-10F, trMCF, bsMCF,... |
|
T36002 |
4-hydroxy Hexenal
|
4-HHE,4-hydroxy Hexenal |
Others
|
|
4-hydroxy Hexenal is a lipid peroxidation product derived from oxidized ω-3 fatty acids such as DHA. [1][2] |
|
T37225 |
(±)7(8)-DiHDPA
|
|
Others
|
|
(±)7(8)-DiHDPA is a major metabolite of docosahexaenoic acid that is produced via oxidation by cytochrome P450 epoxygenases. Epoxygenase metabolites of DHA, including (±)7(8)-DiHDPA, suppress aggregation and thromboxane ... |
|
T35495 |
(±)13(14)-DiHDPA
|
|
Others
|
|
(±)13(14)-DiHDPA is a metabolite of docosahexaenoic acid that is produced via oxidation by cytochrome P450 epoxygenases. Epoxygenase metabolites of DHA, including (±)13(14)-DiHDPA, are reported to inhibit angiogenesis, t... |
|
T37532 |
Docosahexaenoyl Glycine
|
|
|
|
The ω-3 polyunsaturated fatty acids (PUFAs) found in fish oils provide cardiovascular benefits. Docosahexaenoic acid (DHA), a C22:6 PUFA, is the most abundant ω-3 fatty acid in neural tissues, especially in the retina an... |
|
T37235 |
(±)16(17)-EpDPA
|
(±)16,17-EpDPE,(±)16,17 EDP,(±)16,17-epoxy Docosapentaenoic Acid,(±)16,17-epoxy DPA,(±)16(17)-EpDPA |
Others
|
|
EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-de... |
|
T35496 |
(±)13(14)-EpDPA
|
|
Others
|
|
Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers. (±)13(14)-EpDPA is a docosahexaenoic acid epoxygenase metabolite, derived via epoxidation of the 13,14-double bo... |
|
T35493 |
(±)10(11)-EpDPA
|
|
Others
|
|
Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers. (±)10(11)-EpDPA is a docosahexaenoic acid epoxygenase metabolite, derived via epoxidation of the 10,11-double bo... |
|
T35497 |
(±)7(8)-EpDPA
|
|
Others
|
|
Docosahexaenoic acid is the most abundant ω-3 fatty acid in neural tissues, especially in the brain and retina. (±)7(8)-EpDPA is an epoxide derivative of DHA that is generated by the action of cytochrome P450 epoxygenase... |
|
T37503 |
Maresin 2
|
3R,14S-diHDHA |
Others
|
|
Docosahexaenoic acid is an ω-3 fatty acid that is abundant in the brain and the retina and is known to be important in early development.[1] [2] Maresin 2 (MaR2) is a 13R,14S-dihydroxy DHA formed by recombinant human mac... |
|
T37301 |
PCTR2
|
|
Others
|
|
Protein conjugates in tissue regeneration 2 (PCTR2) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid . DHA is oxidized to 16S,17S-epoxy-protectin, which is converted to PCTR1 by glutath... |
